Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Bellicum Pharma Comm (BLCM)

Bellicum Pharma Comm (BLCM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 42,174
  • Shares Outstanding, K 49,616
  • Annual Sales, $ 1,120 K
  • Annual Income, $ -98,040 K
  • 60-Month Beta 1.48
  • Price/Sales 39.02
  • Price/Cash Flow N/A
  • Price/Book 34.44
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.34
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/06/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.50
  • Number of Estimates 2
  • High Estimate -0.49
  • Low Estimate -0.52
  • Prior Year -0.63
  • Growth Rate Est. (year over year) +20.63%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.72 +17.88%
on 10/23/19
1.47 -42.18%
on 11/04/19
-0.01 (-1.04%)
since 10/11/19
3-Month
0.72 +17.88%
on 10/23/19
1.47 -42.18%
on 11/04/19
-0.26 (-23.42%)
since 08/12/19
52-Week
0.72 +17.88%
on 10/23/19
5.44 -84.38%
on 12/04/18
-3.32 (-79.62%)
since 11/12/18

Most Recent Stories

More News
Bellicum Pharmaceuticals Presents Encouraging Preclinical Data for GoCAR-NK Cell Program at Society for Immunotherapy of Cancer Annual Meeting

iMC activation enhances innate NK cell cytotoxicity against tumor cell lines in vitro

BLCM : 0.85 (-3.50%)
Bellicum Pharmaceuticals (BLCM) Reports Q3 Loss, Lags Revenue Estimates

Bellicum Pharmaceuticals (BLCM) delivered earnings and revenue surprises of -1.75% and -65.67%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the...

BLCM : 0.85 (-3.50%)
Bellicum Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Operational Update

Raised gross proceeds of $69.6 million from public offering and private placement option fee

BLCM : 0.85 (-3.50%)
Bellicum Pharmaceuticals Announces Presentation on CAR-NK Cell Program at SITC 2019

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that an abstract for a preclinical investigation from its...

BLCM : 0.85 (-3.50%)
Bellicum Pharmaceuticals to Report Third Quarter 2019 Financial Results and Provide Corporate Update

- Management to host webcast and conference call on Wednesday, November 6, 2019 at 5 p.m. ET / 2 p.m. PT -

BLCM : 0.85 (-3.50%)
Earnings Preview: Bellicum Pharmaceuticals (BLCM) Q3 Earnings Expected to Decline

Bellicum Pharmaceuticals (BLCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BLCM : 0.85 (-3.50%)
Watch for Bellicum Pharmac to Potentially Rebound After Falling 6.77% Yesterday

Bellicum Pharmac (NASDAQ:BLCM) traded in a range yesterday that spanned from a low of $0.82 to a high of $0.95. Yesterday, the shares fell 6.8%, which took the trading range below the 3-day low of $0.85...

BLCM : 0.85 (-3.50%)
Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced an equity inducement...

BLCM : 0.85 (-3.50%)
Top Ranked Momentum Stocks to Buy for September 23rd

Top Ranked Momentum Stocks to Buy for September 23rd

ROAD : 18.32 (+2.46%)
RLGT : 5.52 (+0.18%)
CRTX : 22.67 (-3.53%)
BLCM : 0.85 (-3.50%)
Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced an equity inducement...

BLCM : 0.85 (-3.50%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade BLCM with:

Business Summary

Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on discovering and developing cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. The Company's lead clinical product...

See More

Key Turning Points

2nd Resistance Point 0.94
1st Resistance Point 0.90
Last Price 0.85
1st Support Level 0.81
2nd Support Level 0.77

See More

52-Week High 5.44
Fibonacci 61.8% 3.64
Fibonacci 50% 3.08
Fibonacci 38.2% 2.52
Last Price 0.85
52-Week Low 0.72

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar